Talis Biomedical is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. Co. is developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system comprises an instrument, single-use test cartridges and software that is designed to support a central cloud database, which are designed to provide central laboratory levels of accuracy and be operated by an untrained user. Co. is developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infection. The TLIS stock yearly return is shown above.
The yearly return on the TLIS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TLIS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|